[
    {
        "id": "wiki20220301en009_170534",
        "title": "Statin",
        "content": "Cognitive effects Multiple systematic reviews and meta-analyses have concluded that the available evidence does not support an association between statin use and cognitive decline. Statins have been shown to decrease the risk of dementia, Alzheimer's disease, and improve cognitive impairment in some cases. Additionally, both the Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) study and the Health Protection Study (HPS) demonstrated that simvastatin and pravastatin did not affect cognition for patients with risk factors for, or a history of, vascular diseases. There are reports of reversible cognitive impairment with statins. The U.S. Food and Drug Administration (FDA) package insert on statins includes a warning about the potential for non-serious and reversible cognitive side effects with the medication (memory loss, confusion).",
        "contents": "Statin. Cognitive effects Multiple systematic reviews and meta-analyses have concluded that the available evidence does not support an association between statin use and cognitive decline. Statins have been shown to decrease the risk of dementia, Alzheimer's disease, and improve cognitive impairment in some cases. Additionally, both the Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) study and the Health Protection Study (HPS) demonstrated that simvastatin and pravastatin did not affect cognition for patients with risk factors for, or a history of, vascular diseases. There are reports of reversible cognitive impairment with statins. The U.S. Food and Drug Administration (FDA) package insert on statins includes a warning about the potential for non-serious and reversible cognitive side effects with the medication (memory loss, confusion).",
        "wiki_id": "178197"
    },
    {
        "id": "wiki20220301en009_170528",
        "title": "Statin",
        "content": "No studies have examined the effect of statins on cognition in patients with prior stroke. However, two large studies (HPS and PROSPER) that included people with vascular diseases reported that simvastatin and pravastatin did not impact cognition. Statins have been studied for improving operative outcomes in cardiac and vascular surgery. Mortality and adverse cardiovascular events were reduced in statin groups. Older adults who receive statin therapy at time of discharge from the hospital after an inpatient stay have been studied. People with cardiac ischemia not previously on statins at the time of admission have a lower risk of major cardiac adverse events and hospital readmission two years post-hospitalization. Comparative effectiveness While no direct comparison exists, all statins appear effective regardless of potency or degree of cholesterol reduction. Simvastatin and pravastatin appear to have a reduced incidence of side-effects.",
        "contents": "Statin. No studies have examined the effect of statins on cognition in patients with prior stroke. However, two large studies (HPS and PROSPER) that included people with vascular diseases reported that simvastatin and pravastatin did not impact cognition. Statins have been studied for improving operative outcomes in cardiac and vascular surgery. Mortality and adverse cardiovascular events were reduced in statin groups. Older adults who receive statin therapy at time of discharge from the hospital after an inpatient stay have been studied. People with cardiac ischemia not previously on statins at the time of admission have a lower risk of major cardiac adverse events and hospital readmission two years post-hospitalization. Comparative effectiveness While no direct comparison exists, all statins appear effective regardless of potency or degree of cholesterol reduction. Simvastatin and pravastatin appear to have a reduced incidence of side-effects.",
        "wiki_id": "178197"
    },
    {
        "id": "wiki20220301en020_68177",
        "title": "Hypercholesterolemia",
        "content": "Medication Statins are the typically used medications, in addition to healthy lifestyle interventions. Statins can reduce total cholesterol by about 50% in the majority of people, and are effective in reducing the risk of cardiovascular disease in both people with and without pre-existing cardiovascular disease. In people without cardiovascular disease, statins have been shown to reduce all-cause mortality, fatal and non-fatal coronary heart disease, and strokes. Greater benefit is observed with the use of high-intensity statin therapy. Statins may improve quality of life when used in people without existing cardiovascular disease (i.e. for primary prevention). Statins decrease cholesterol in children with hypercholesterolemia, but no studies as of 2010 show improved outcomes and diet is the mainstay of therapy in childhood.",
        "contents": "Hypercholesterolemia. Medication Statins are the typically used medications, in addition to healthy lifestyle interventions. Statins can reduce total cholesterol by about 50% in the majority of people, and are effective in reducing the risk of cardiovascular disease in both people with and without pre-existing cardiovascular disease. In people without cardiovascular disease, statins have been shown to reduce all-cause mortality, fatal and non-fatal coronary heart disease, and strokes. Greater benefit is observed with the use of high-intensity statin therapy. Statins may improve quality of life when used in people without existing cardiovascular disease (i.e. for primary prevention). Statins decrease cholesterol in children with hypercholesterolemia, but no studies as of 2010 show improved outcomes and diet is the mainstay of therapy in childhood.",
        "wiki_id": "513039"
    },
    {
        "id": "wiki20220301en093_9135",
        "title": "Asymmetric dimethylarginine",
        "content": "Direct alteration of ADMA levels with supplements of L-arginine have been suggested. The hope is that such intervention might not only improve endothelial function but also reduce clinical symptoms of overt cardiovascular disease. However studies show inconsistency in results in a clinical context, and the recent results with manipulating homocysteine levels warrant extreme care with what clinical outcomes might arise from this approach. Statins, as well as affecting circulating cholesterol levels, also increase nitric oxide levels and so have a direct effect on blood supply to the heart. Elevated levels of ADMA seems to modify this effect and so may have consequences for patients' responsiveness to taking statins. Repeated administration of d-amphetamine may decrease ADMA. See also Arginine Hypertension Protein detoxification Vasoconstriction References External links ADMA article, Medical News Today, March 27, 2006 Summary of ADMA research literature www.adma.com",
        "contents": "Asymmetric dimethylarginine. Direct alteration of ADMA levels with supplements of L-arginine have been suggested. The hope is that such intervention might not only improve endothelial function but also reduce clinical symptoms of overt cardiovascular disease. However studies show inconsistency in results in a clinical context, and the recent results with manipulating homocysteine levels warrant extreme care with what clinical outcomes might arise from this approach. Statins, as well as affecting circulating cholesterol levels, also increase nitric oxide levels and so have a direct effect on blood supply to the heart. Elevated levels of ADMA seems to modify this effect and so may have consequences for patients' responsiveness to taking statins. Repeated administration of d-amphetamine may decrease ADMA. See also Arginine Hypertension Protein detoxification Vasoconstriction References External links ADMA article, Medical News Today, March 27, 2006 Summary of ADMA research literature www.adma.com",
        "wiki_id": "4533264"
    },
    {
        "id": "wiki20220301en087_27871",
        "title": "Adherence (medicine)",
        "content": "The World Health Organization (WHO) estimated in 2003 that only 50% of people complete long-term therapy for chronic illnesses as they were prescribed, which puts patient health at risk. For example, in 2002 statin compliance dropped to between 25–40% after two years of treatment, with patients taking statins for what they perceive to be preventative reasons being unusually poor compliers. A wide variety of packaging approaches have been proposed to help patients complete prescribed treatments. These approaches include formats that increase the ease of remembering the dosage regimen as well as different labels for increasing patient understanding of directions. For example, medications are sometimes packed with reminder systems for the day and/or time of the week to take the medicine. Some evidence shows that reminder packaging may improve clinical outcomes such as blood pressure.",
        "contents": "Adherence (medicine). The World Health Organization (WHO) estimated in 2003 that only 50% of people complete long-term therapy for chronic illnesses as they were prescribed, which puts patient health at risk. For example, in 2002 statin compliance dropped to between 25–40% after two years of treatment, with patients taking statins for what they perceive to be preventative reasons being unusually poor compliers. A wide variety of packaging approaches have been proposed to help patients complete prescribed treatments. These approaches include formats that increase the ease of remembering the dosage regimen as well as different labels for increasing patient understanding of directions. For example, medications are sometimes packed with reminder systems for the day and/or time of the week to take the medicine. Some evidence shows that reminder packaging may improve clinical outcomes such as blood pressure.",
        "wiki_id": "4116856"
    },
    {
        "id": "wiki20220301en010_14741",
        "title": "Thrombosis",
        "content": "reperfusion in acute ischemic conditions to improve clinical outcomes. Therapeutic strategies that have potential to improve clinical outcomes in reperfused STEMI patients include remote ischemic conditioning (RIC), exenatide, and metoprolol. These have emerged amongst a multitude of cardioprotective interventions investigated with largely neutral clinical data. Of these, RIC has the most robust clinical evidence, especially in the context of STEMI, but also emerging for other indications such as acute ischemic stroke and aneurysmal subarachnoid hemorrhage.",
        "contents": "Thrombosis. reperfusion in acute ischemic conditions to improve clinical outcomes. Therapeutic strategies that have potential to improve clinical outcomes in reperfused STEMI patients include remote ischemic conditioning (RIC), exenatide, and metoprolol. These have emerged amongst a multitude of cardioprotective interventions investigated with largely neutral clinical data. Of these, RIC has the most robust clinical evidence, especially in the context of STEMI, but also emerging for other indications such as acute ischemic stroke and aneurysmal subarachnoid hemorrhage.",
        "wiki_id": "183048"
    },
    {
        "id": "wiki20220301en004_95409",
        "title": "Coenzyme Q10",
        "content": "Assessment Although CoQ10 may be measured in blood plasma, these measurements reflect dietary intake rather than tissue status. Currently, most clinical centers measure CoQ10 levels in cultured skin fibroblasts, muscle biopsies, and blood mononuclear cells. Culture fibroblasts can be used also to evaluate the rate of endogenous CoQ10 biosynthesis, by measuring the uptake of 14C-labelled p-hydroxybenzoate. Statins It has been suggested that the myotoxicity of statins is due to impairment of CoQ biosynthesis, but the evidence supporting this was deemed controversial in 2011. While statins may reduce coenzyme Q10 in the blood it is unclear if they reduce coenzyme Q10 in muscle. Evidence does not support that supplementation improves side effects from statins. However, a more recent metanalysis concluded that, \"CoQ10 supplementation ameliorated SAMSs, implying that CoQ10 supplementation might be a complementary approach to ameliorate statin‐induced myopathy.\" Dietary supplement",
        "contents": "Coenzyme Q10. Assessment Although CoQ10 may be measured in blood plasma, these measurements reflect dietary intake rather than tissue status. Currently, most clinical centers measure CoQ10 levels in cultured skin fibroblasts, muscle biopsies, and blood mononuclear cells. Culture fibroblasts can be used also to evaluate the rate of endogenous CoQ10 biosynthesis, by measuring the uptake of 14C-labelled p-hydroxybenzoate. Statins It has been suggested that the myotoxicity of statins is due to impairment of CoQ biosynthesis, but the evidence supporting this was deemed controversial in 2011. While statins may reduce coenzyme Q10 in the blood it is unclear if they reduce coenzyme Q10 in muscle. Evidence does not support that supplementation improves side effects from statins. However, a more recent metanalysis concluded that, \"CoQ10 supplementation ameliorated SAMSs, implying that CoQ10 supplementation might be a complementary approach to ameliorate statin‐induced myopathy.\" Dietary supplement",
        "wiki_id": "97574"
    },
    {
        "id": "wiki20220301en009_170525",
        "title": "Statin",
        "content": "The National Institute for Health and Clinical Excellence (NICE) recommends statin treatment for adults with an estimated 10 year risk of developing cardiovascular disease that is greater than 10%. Guidelines by the American College of Cardiology and the American Heart Association recommend statin treatment for primary prevention of cardiovascular disease in adults with LDL cholesterol ≥ 190 mg/dL or those with diabetes, age 40–75 with LDL-C 70–190 mg/dl; or in those with a 10-year risk of developing heart attack or stroke of 7.5% or more. In this latter group, statin assignment was not automatic, but was recommended to occur only after a clinician-patient risk discussion with shared decision making where other risk factors and lifestyle are addressed, the potential for benefit from a statin is weighed against the potential for adverse effects or drug interactions and informed patient preference is elicited. Moreover, if a risk decision was uncertain, factors such as family history,",
        "contents": "Statin. The National Institute for Health and Clinical Excellence (NICE) recommends statin treatment for adults with an estimated 10 year risk of developing cardiovascular disease that is greater than 10%. Guidelines by the American College of Cardiology and the American Heart Association recommend statin treatment for primary prevention of cardiovascular disease in adults with LDL cholesterol ≥ 190 mg/dL or those with diabetes, age 40–75 with LDL-C 70–190 mg/dl; or in those with a 10-year risk of developing heart attack or stroke of 7.5% or more. In this latter group, statin assignment was not automatic, but was recommended to occur only after a clinician-patient risk discussion with shared decision making where other risk factors and lifestyle are addressed, the potential for benefit from a statin is weighed against the potential for adverse effects or drug interactions and informed patient preference is elicited. Moreover, if a risk decision was uncertain, factors such as family history,",
        "wiki_id": "178197"
    },
    {
        "id": "wiki20220301en013_95798",
        "title": "Biofeedback",
        "content": "Whatmore and Kohli (1968) introduced the concept of dysponesis (misplaced effort) to explain how functional disorders (where body activity is disturbed) develop. Bracing your shoulders when you hear a loud sound illustrates dysponesis, since this action does not protect against injury. These clinicians applied EMG biofeedback to diverse functional problems like headache and hypertension. They reported case follow-ups ranging from 6 to 21 years. This was long compared with typical 0-24 month follow-ups in the clinical literature. Their data showed that skill in controlling misplaced efforts was positively related to clinical improvement. Last, they wrote The Pathophysiology and Treatment of Functional Disorders (1974) that outlined their treatment of functional disorders. Wolf (1983) integrated EMG biofeedback into physical therapy to treat stroke patients and conducted landmark stroke outcome studies.",
        "contents": "Biofeedback. Whatmore and Kohli (1968) introduced the concept of dysponesis (misplaced effort) to explain how functional disorders (where body activity is disturbed) develop. Bracing your shoulders when you hear a loud sound illustrates dysponesis, since this action does not protect against injury. These clinicians applied EMG biofeedback to diverse functional problems like headache and hypertension. They reported case follow-ups ranging from 6 to 21 years. This was long compared with typical 0-24 month follow-ups in the clinical literature. Their data showed that skill in controlling misplaced efforts was positively related to clinical improvement. Last, they wrote The Pathophysiology and Treatment of Functional Disorders (1974) that outlined their treatment of functional disorders. Wolf (1983) integrated EMG biofeedback into physical therapy to treat stroke patients and conducted landmark stroke outcome studies.",
        "wiki_id": "292906"
    },
    {
        "id": "wiki20220301en159_18149",
        "title": "TIMI",
        "content": "MERLIN-TIMI 36 evaluated a novel anti-ischemic agent, ranolazine, in patients with acute coronary syndromes. TIMI 37A evaluated the efficacy, safety, and pharmacokinetics of INO-1001, a poly(ADP-ribose) polymerase in patients with ST-segment elevation myocardial infarction. TRITON-TIMI 38 evaluated prasugrel compared with clopidogrel in patients with acute coronary syndromes. EARLY ACS-(TIMI 39) assessed the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST segment elevation acute coronary syndrome. IMPROVE-IT (TIMI 40) determined whether the addition of ezetimibe to statin therapy, using ezetimibe/simvastatin, improves cardiovascular outcomes compared with simvastatin monotherapy in patients after ACS. In addition, the difference in achieved LDL-C levels between the groups provided data on whether the target for LDL-C lowering should be reduced further.",
        "contents": "TIMI. MERLIN-TIMI 36 evaluated a novel anti-ischemic agent, ranolazine, in patients with acute coronary syndromes. TIMI 37A evaluated the efficacy, safety, and pharmacokinetics of INO-1001, a poly(ADP-ribose) polymerase in patients with ST-segment elevation myocardial infarction. TRITON-TIMI 38 evaluated prasugrel compared with clopidogrel in patients with acute coronary syndromes. EARLY ACS-(TIMI 39) assessed the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST segment elevation acute coronary syndrome. IMPROVE-IT (TIMI 40) determined whether the addition of ezetimibe to statin therapy, using ezetimibe/simvastatin, improves cardiovascular outcomes compared with simvastatin monotherapy in patients after ACS. In addition, the difference in achieved LDL-C levels between the groups provided data on whether the target for LDL-C lowering should be reduced further.",
        "wiki_id": "11225718"
    },
    {
        "id": "wiki20220301en002_160981",
        "title": "Endometriosis",
        "content": "During fertility treatment, the ultralong pretreatment with GnRH-agonist has a higher chance of resulting in pregnancy for individuals with endometriosis, compared to the short pretreatment. Research Preliminary research on mouse models showed that monoclonal antibodies, as well as inhibitors of MyD88 downstream signaling pathway, can reduce lesion volume. Thanks to that, clinical trials are being done on using a monoclonal antibody directed against IL-33 and using anakinra, an IL-1 receptor antagonist. Promising preclinical outcomes is pushing clinical trials into testing cannabinoid extracts, dichloroacetic acid and curcuma capsules.",
        "contents": "Endometriosis. During fertility treatment, the ultralong pretreatment with GnRH-agonist has a higher chance of resulting in pregnancy for individuals with endometriosis, compared to the short pretreatment. Research Preliminary research on mouse models showed that monoclonal antibodies, as well as inhibitors of MyD88 downstream signaling pathway, can reduce lesion volume. Thanks to that, clinical trials are being done on using a monoclonal antibody directed against IL-33 and using anakinra, an IL-1 receptor antagonist. Promising preclinical outcomes is pushing clinical trials into testing cannabinoid extracts, dichloroacetic acid and curcuma capsules.",
        "wiki_id": "53335"
    },
    {
        "id": "wiki20220301en023_84339",
        "title": "Stroke",
        "content": "Tight blood sugar control in the first few hours does not improve outcomes and may cause harm. High blood pressure is also not typically lowered as this has not been found to be helpful. Cerebrolysin, a mix of pig brain tissue used to treat acute ischemic stroke in many Asian and European countries, does not improve outcomes and may increase the risk of severe adverse events.",
        "contents": "Stroke. Tight blood sugar control in the first few hours does not improve outcomes and may cause harm. High blood pressure is also not typically lowered as this has not been found to be helpful. Cerebrolysin, a mix of pig brain tissue used to treat acute ischemic stroke in many Asian and European countries, does not improve outcomes and may increase the risk of severe adverse events.",
        "wiki_id": "625404"
    },
    {
        "id": "wiki20220301en032_48091",
        "title": "Ezetimibe/simvastatin",
        "content": "Clinical trials IMPROVE-IT trial Published in 2015, the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) randomized 18,144 patients with ACS to simvastatin 40 mg/d plus ezetimibe 10 mg/d or simvastatin alone. With median follow-up of 6 years, simvastatin+ezetimibe was found to reduce the primary outcome of CV mortality, major CV event, or nonfatal stroke (34.7% vs. 32.7%; P=0.016; NNT 50 per 7 years or NNT 350 per 1 year ). There was no reduction in all-cause or CV mortality with simvastatin+ezetimibe, though there was a reduction in MI and stroke.",
        "contents": "Ezetimibe/simvastatin. Clinical trials IMPROVE-IT trial Published in 2015, the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) randomized 18,144 patients with ACS to simvastatin 40 mg/d plus ezetimibe 10 mg/d or simvastatin alone. With median follow-up of 6 years, simvastatin+ezetimibe was found to reduce the primary outcome of CV mortality, major CV event, or nonfatal stroke (34.7% vs. 32.7%; P=0.016; NNT 50 per 7 years or NNT 350 per 1 year ). There was no reduction in all-cause or CV mortality with simvastatin+ezetimibe, though there was a reduction in MI and stroke.",
        "wiki_id": "1004541"
    },
    {
        "id": "wiki20220301en023_84372",
        "title": "Stroke",
        "content": "30 to 50% of stroke survivors suffer post-stroke depression, which is characterized by lethargy, irritability, sleep disturbances, lowered self-esteem and withdrawal. Depression can reduce motivation and worsen outcome, but can be treated with social and family support, psychotherapy and, in severe cases, antidepressants. Psychotherapy sessions may have a small effect on improving mood and preventing depression after a stroke, however psychotherapy does not appear to be effective at treating depression after a stroke. Antidepressant medications may be useful for treating depression after a stroke.",
        "contents": "Stroke. 30 to 50% of stroke survivors suffer post-stroke depression, which is characterized by lethargy, irritability, sleep disturbances, lowered self-esteem and withdrawal. Depression can reduce motivation and worsen outcome, but can be treated with social and family support, psychotherapy and, in severe cases, antidepressants. Psychotherapy sessions may have a small effect on improving mood and preventing depression after a stroke, however psychotherapy does not appear to be effective at treating depression after a stroke. Antidepressant medications may be useful for treating depression after a stroke.",
        "wiki_id": "625404"
    },
    {
        "id": "wiki20220301en009_170558",
        "title": "Statin",
        "content": "misleading claims exaggerating the adverse effects of statins had received widespread media coverage, with a consequent negative impact to public health. Controversy over the effectiveness of statins in the medical literature was amplified in popular media in the early 2010s, leading an estimated 200,000 people in the UK to stop using statins over a six-month period to mid 2016, according to the authors of a study funded by the British Heart Foundation. They estimated that there could be up to 2,000 extra heart attacks or strokes over the following 10 years as a consequence. An unintended effect of the academic statin controversy has been the spread of scientifically questionable alternative therapies. Cardiologist Steven Nissen at Cleveland Clinic commented \"We are losing the battle for the hearts and minds of our patients to Web sites...\" promoting unproven medical therapies. Harriet Hall sees a spectrum of \"statin denialism\" ranging from pseudoscientific claims to the",
        "contents": "Statin. misleading claims exaggerating the adverse effects of statins had received widespread media coverage, with a consequent negative impact to public health. Controversy over the effectiveness of statins in the medical literature was amplified in popular media in the early 2010s, leading an estimated 200,000 people in the UK to stop using statins over a six-month period to mid 2016, according to the authors of a study funded by the British Heart Foundation. They estimated that there could be up to 2,000 extra heart attacks or strokes over the following 10 years as a consequence. An unintended effect of the academic statin controversy has been the spread of scientifically questionable alternative therapies. Cardiologist Steven Nissen at Cleveland Clinic commented \"We are losing the battle for the hearts and minds of our patients to Web sites...\" promoting unproven medical therapies. Harriet Hall sees a spectrum of \"statin denialism\" ranging from pseudoscientific claims to the",
        "wiki_id": "178197"
    }
]